We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
AHS
826
Aspiriant Holdings S3
California
$3.51M +$10.4K +359 +0.3%
WSTAM
827
Wilbanks Smith & Thomas Asset Management
Virginia
$3.5M -$475K -16,319 -12%
LNWWM
828
Laird Norton Wetherby Wealth Management
California
$3.5M -$10.3K -355 -0.3%
SNT
829
Security National Trust
West Virginia
$3.48M -$107K -3,689 -3%
QCMC
830
Quantum Capital Management (California)
California
$3.46M +$166K +5,691 +5%
JFGIW
831
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$3.46M +$124K +4,249 +4%
SA
832
Strategic Advisors
New York
$3.45M +$31.3K +1,075 +0.9%
BCA
833
Benchmark Capital Advisors
New York
$3.45M -$241K -8,274 -7%
CCM
834
Crossvault Capital Management
Texas
$3.42M +$3.43M +117,841 New
SHGA
835
Sand Hill Global Advisors
California
$3.4M -$993K -34,135 -23%
LOCB
836
Lombard Odier & Cie (Bahamas)
Bahamas
$3.4M +$3.4M +116,820 New
AAIM
837
American Assets Investment Management
California
$3.39M
MCM
838
McMillion Capital Management
North Carolina
$3.39M -$59.5K -2,046 -2%
SGH
839
Schonfeld Group Holdings
New York
$3.38M +$3.39M +116,423 New
IPRC
840
Indices-Pac Research Corporation
New Jersey
$3.38M +$414K +14,210 +14%
BA
841
Bridgewater Associates
Connecticut
$3.38M +$1.71M +58,813 +102%
MPAM
842
Murphy Pohlad Asset Management
Minnesota
$3.37M -$284K -9,775 -8%
TF
843
Tompkins Financial
New York
$3.36M +$142K +4,894 +4%
FHA
844
First Horizon Advisors
Tennessee
$3.36M -$13.5K -464 -0.4%
WFG
845
Windsor Financial Group
Minnesota
$3.3M -$29.8K -1,024 -0.9%
BHB
846
Bank Hapoalim BM
Israel
$3.28M +$3.28M +112,832 New
TRIM
847
Thompson Rubinstein Investment Management
Oregon
$3.28M +$9.23K +317 +0.3%
SFSIG
848
San Francisco Sentry Investment Group
California
$3.27M +$7.22K +248 +0.2%
CD
849
Carl Domino
Florida
$3.25M -$220K -7,564 -6%
CFA
850
Carroll Financial Associates
North Carolina
$3.24M -$333K -11,437 -9%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.